Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Press release popped up while I was checking my email...lol
Not much new information but I hope it’s enough to start moving up.
Paying off Magna is a hugeaccomplishment.
Propanc Biopharma Repays Magna Invests Senior Secured Convertible Debentures
DOWNLOAD AS PDF January 05, 2018
CEO Views as "Positive First Step" towards Restructuring Balance Sheet to Attract Long Term Investors
MELBOURNE, Australia, Jan. 5, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has repaid in full all outstanding debt to Magna Invests. Of the $4.7 million in senior secured debt originally borrowed from Magna Invests, a total of $507,080.62 in principal and accrued interest remained outstanding, which amount has now been repaid with the net proceeds of a one-year, 8% unsecured convertible redeemable note in the principal amount of $532,434.65 issued to Eagle Equities, LLC, an existing investor of the Company. There is a six month holding period until the note fully matures and becomes redeemable. The payoff to Magna Invests represents a positive first step towards its goal of restructuring the debt on the Company's balance sheet, as it looks towards attracting long term investors to raise capital for a First-In-Human study in 2018 and increasing the Company's investment and liquidity profile.
(PRNewsfoto/Propanc Biopharma)
"I am pleased with the opportunity to repay all of our most onerous debt, including all outstanding secured debt, in full, as it helps us gather some momentum in our efforts towards attracting long term investors to support our plans to progress our lead product, PRP, into clinical trials," said James Nathanielsz, Propanc Biopharma's Chief Executive Officer.
Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
I averaged down to .94 cents.
Its my understanding that the conference was cancelled due to the wildfires in California. Hopefully they will release information or inform us about the rescheduling of the event.
From what I can see it's about 3mil shares.
The moment they announce the start of clinical trials I believe it will.
Im buying what I can.
That doesn't include beneficial owners. I haven't been able to find information on beneficial owners. I don't believe it to be more than a couple of hundred based on the trade activity. Even on the day when the volume was over 300k there was less than 200 trades.
We need new investors. As of April 2017 there were only 82 recorded shareholders. We're invisible to most of the market. Announcement of the US Patent once the assignee correction is made will move it a little but we need the clinical trials to start in order to attention from big investors.
The drug has been granted orphan status during development but the drug itself has not been Granted FDA approval yet.
In Europe
I get my Patent information directly from the US Patent website not any news outlets. Should be easier to find now that they have issued a patent number.
Propanc issued US Patent. Issue date 5/2/2017 Patent Number 9636359. Intellectual Property portfolio growing.
I owned millions and I'm still here.
Issue notification US Patent.
https://drive.google.com/file/d/0Bz_eN9hWweTrX3NBOXJ0V29iSDQ/view?usp=drivesdk
4/12/2017 issue notification mailed regarding PPCH US Patent. About two weeks before Patent Number is assigned.
They authorized a reverse split but didn’t announce a date. I think they want to get the price up a little with the news that will be coming soon and then use the split to push the price higher for up listing. IMO.
Sure. Why do you think that? I have other penny stocks that have reversed split and the companies are still in business. Plus like you have said in the past why sale when the shares are free.
Don't understand why people would sell this low right before major announcements knowing that the the US Patent has been approved. Its in Final Data Capture being prepared for issue. I think I'll buy more.
Issuance fees were paid this weekend. Patent will be assigned sometime this week.
Yeah. You're never going to get to it that way. You have to search for the Application number 13502917, PCT number pct/au2010/001403, Publication number 20120251516...etc
3/17/2017 Propanc pays US Patent issuance fees. Patent to be assigned soon.
It's a simple search. I don't understand why you can't find any information.
Erin M Bowers was the primary examiner. As far as their qualifications you have to check with the United States Patent and Trademarks office or the Department of Commerce since they are an employee of one of them.
They withdraw the application. Needed more clinical data.
Important dates approaching. Middle and high dose toxicology ends next week. US Patent notice of allowance payment deadline is 3/22/17. Examiner's notes on allowance is very encouraging. All rejections were dismissed. Basically saying all claims are valid. Don't know why the issue fees have not been paid or maybe they have and the site is not current. The next few weeks should tell if this company is for real with moving forward and creating value.
I'll try to find another way to get on the board.
Choose publication number.
These are the sites that I use.
https://www.uspto.gov/
http://www.wipo.int/portal/en/
Direct link
Enter the CAPTCHA
Choose publication application
Enter 20120251516
Should take you directly to the application
http://portal.uspto.gov/pair/PublicPair
Do you mean the the notice of allowance on the US Patent site? If so it's very easy to find. I've been able to find the majority of the applications and filings that ppch announce. What's your evidence that the company is fake. By the way a majority of the companies on any exchange are pump and dump. That doesn't mean that they are fake. Buy low sell high is a pump and dump strategy.
West coast is up and bidding.
World intellectual property organizations website most current current information.
https://patentscope.wipo.int/search/en/detail.jsf?docId=EP179901227&recNum=9&maxRec=935&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=Trypsinogen+and+chymotrypsinogen+&tab=PCTDescription
I see you guys found it. I've been working to connect the dots. Notice one of the inventors has a connection to the university of Bath. I have found other connections to the university of of jaen also.